NSCLC cells treated with Gefitinib
Ontology highlight
ABSTRACT: About 10% of all NSCLC patients respond to gefitnib treatment and all of these patients will acquire resistance to the EGFR TKI. We used microarray to look at global gene expression changes in untreated cells vs gefitinib treated cells to identify key characters for the acquisition of resistance. NSCLC cells, H322c, were cultured 4 days in media containing 1?M gefitinib or 0.1% DMSO as a control. On day 4, RNA was extracted and submitted for microarray hybridization.
ORGANISM(S): Homo sapiens
SUBMITTER: Kathryn Ware
PROVIDER: E-GEOD-23206 | biostudies-arrayexpress |
REPOSITORIES: biostudies-arrayexpress
ACCESS DATA